文献速递其他结缔组织病

弥漫性系统性硬化症器官损害进展预测因素:EUSTAR分析

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.
PubMed 文献 · Ann Rheum Dis · 2019-06-21

该研究基于欧洲硬皮病试验与研究组数据库,纳入1451例弥漫性系统性硬化症患者,以新发肾危象、肺或心脏功能下降、新发肺动脉高压或死亡为疾病恶化终点,通过多重插补和LASSO回归从42个临床参数中筛选预测因素,最终模型保留8个预测因子,其中年龄、活动性指端溃疡、肺纤维化、肌无力和CRP升高与疾病进展强烈相关。

要点

  • 年龄、活动性指端溃疡、肺纤维化、肌无力和CRP升高与疾病进展强烈相关。
  • 活动性指端溃疡、CRP升高、肺纤维化和肌无力与进展时间显著缩短相关。

核心结论

  • 年龄、活动性指端溃疡、肺纤维化、肌无力和CRP升高是弥漫性系统性硬化症疾病恶化的预测因素。
  • 活动性指端溃疡、CRP升高、肺纤维化和肌无力与显著缩短的疾病进展时间相关。

研究设计与样本

  • 研究基于欧洲硬皮病试验与研究组数据库,纳入弥漫性系统性硬化症且随访12±3个月的患者。
  • 共1451例患者符合纳入标准,其中706例具有完整结局参数数据并纳入分析。
  • 从42个临床参数中,采用多重插补处理缺失数据和LASSO回归筛选预测因素。

主要发现

  • 42个候选预测因素中,8个保留在最终回归模型。
  • 年龄、活动性指端溃疡、肺纤维化、肌无力和CRP升高与疾病进展强烈相关。
  • 活动性指端溃疡、CRP升高、肺纤维化和肌无力与显著缩短的疾病进展时间相关。

关键数值与推荐

  • 疾病恶化/器官进展定义为发生以下任一事件:新发肾危象、肺或心脏功能下降、新发超声心动图疑似肺动脉高压或死亡。

临床怎么用

  • 这些预测因素可用于在系统性硬化症临床试验中富集存在整体疾病恶化风险的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mortality and worsening of organ function are desirable endpoints for clinical trials in systemic sclerosis (SSc). The aim of this study was to identify factors that allow enrichment of patients with these endpoints, in a population of patients from the European Scleroderma Trials and Research group database. METHODS: Inclusion criteria were diagnosis of diffuse SSc and follow-up over 12±3 months. Disease worsening/organ progression was fulfilled if any of the following events occurred: new renal crisis; decrease of lung or heart function; new echocardiography-suspected pulmonary hypertension or death. In total, 42 clinical parameters were chosen as predictors for the analysis by using (1) imputation of missing data on the basis of multivariate imputation and (2) least absolute shrinkage and selection operator regression. RESULTS: Of 1451 patients meeting the inclusion criteria, 706 had complete data on outcome parameters and were included in the analysis. Of the 42 outcome predictors, eight remained in the final regression model. There was substantial evidence for a strong association between disease progression and age, active digital ulcer (DU), lung fibrosis, muscle weakness and elevated C-reactive protein (CRP) level. Active DU, CRP elevation, lung fibrosis and muscle weakness were also associated with a significantly shorter time to disease progression. A bootstrap validation step with 10 000 repetitions successfully validated the model. CONCLUSIONS: The use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Becker M, Graf N, Sauter R, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis. 2019. PMID: 31227488. doi:10.1136/annrheumdis-2019-215145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。